Last updated: February 24, 2026
What is the drug associated with NDC 70954-0015?
The NDC 70954-0015 corresponds to Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antagonist approved by the FDA for the treatment of rheumatoid arthritis (RA). It is also under investigation for other inflammatory conditions, such as COVID-19-related cytokine release syndrome.
Market Overview
Indications and Approved Uses
- FDA-approved: Rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to other DMARDs.
- Off-label/Investigative: COVID-19-associated cytokine storm, though clearance for this use is limited and under clinical trial.
Competitive Landscape
- Main competitors:
- Tocilizumab (Actemra)
- Sarilumab's primary competitors are other IL-6 inhibitors.
- Market size estimation (2022):
- US rheumatoid arthritis treatment market valued at $10 billion annually.
- IL-6 inhibitors hold approximately 20% of the RA biologic segment.
- Estimated sales potential for sarilumab (Kevzara) in RA is approximately $300 million domestically.
Market Dynamics
- Patents:
- Kevzara’s original patent expired in 2023, opening potential for biosimilar competition.
- Pricing (US):
- Average wholesale price (AWP): approximately $2,700 per dose.
- Dosing: 200 mg subcutaneously every two weeks.
- Approximate annual treatment cost per patient: $35,000.
- Adoption:
- Market penetration remains moderate due to competition and physician preference for established therapies like tocilizumab.
Regulatory Developments
- Biosimilar pipeline:
- Multiple biosimilars are in late-stage development, targeting price competition.
- Post-approval evidence:
- Data supports efficacy similar to other IL-6 inhibitors but indicates slightly lower market share due to brand recognition.
Price Projections (2023–2028)
Revenue Forecast
| Year |
Projected US Sales |
Assumptions |
| 2023 |
$150 million |
Early stage, cautious adoption and biosimilar competition emerges |
| 2024 |
$225 million |
Market expansion as biosimilars enter and prescriber familiarity grows |
| 2025 |
$300 million |
Increased biosimilar availability, potential price erosion but larger patient base |
| 2026 |
$350 million |
Market stabilizes with multiple biosimilars, slight price reduction observed |
| 2027 |
$400 million |
Adoption plateaus, biosimilar options driven by competitive pricing |
| 2028 |
$430 million |
Maturation of the biosimilar market, slight revenue increase from new indications |
Price Erosion Trends
- Biosimilar entry expected to decrease average drug price by 20%–30% within two years of launch.
- Brand pricing steady initially, then decline as biosimilars gain market share.
Key Market Drivers and Risks
Drivers
- Growing prevalence of RA and other inflammatory diseases.
- Patent expiry creating biosimilar competition.
- Demonstrated efficacy and safety profile.
Risks
- Slower biosimilar adoption due to physician and payer resistance.
- Potential regulatory hurdles for biosimilar approval.
- Pricing pressures from payers and formulary restrictions.
Summary
NDC 70954-0015 (Kevzara) is projected to see moderate growth in revenue over the next five years, driven by increasing RA patient numbers and biosimilar competition. Pricing is expected to decline by approximately 20%–30% as biosimilars enter the market. Long-term success will depend on patent expirations, biosimilar market penetration, and clinical positioning.
Key Takeaways
- The RA biologics market is approaching increased biosimilar competition, pressuring prices.
- Sales forecasts indicate growth into 2027, with a plateau expected as market saturation occurs.
- Current price per dose is about $2,700; biosimilar entry could reduce prices significantly.
- Market expansion depends on additional indications and prescriber acceptance.
- Patent expiry in 2023 opens opportunities for biosimilars, potentially altering market dynamics.
FAQs
Q1: When are biosimilars for Kevzara expected to enter the market?
A1: Biosimilar candidates are in late-stage development, with some expected approval as early as 2024.
Q2: How does Kevzara's pricing compare to competitors?
A2: Similar IL-6 inhibitors like tocilizumab (Actemra) have comparable prices, but biosimilars will drive prices down.
Q3: What factors could impact Kevzara’s market share?
A3: Increased biosimilar competition, physician preference, and payer formulary restrictions.
Q4: Are there new indications that could boost sales?
A4: Trials for COVID-19 cytokine storm management have been conducted, but regulatory approval remains limited.
Q5: What strategies could extend Kevzara’s market viability?
A5: Developing new indications, improving dosing convenience, and market differentiation through clinical evidence.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. (2022). Approval documents for sarilumab.
[3] EvaluatePharma. (2022). Biologic Market Forecast.
